Pragmatic Evaluation of Respiratory Distress Syndrome Treatment in Africa

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE4

Total Enrollment

1512 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-01-01

Study Completion Date

2027-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this pragmatic clinical trial is to learn if the drug surfactant given by a less invasive technique works to treat respiratory distress in preterm infants in low- and middle-income African countries where invasive ventilators are unavailable. It will also learn about the safety of the less invasive surfactant administration (LISA) technique. The main questions it aims to answer are:

Does surfactant given by a less invasive surfactant administration technique improve survival in preterm infants in low- and middle-income countries? What medical problems do participants have when receiving surfactant given by the less invasive surfactant administration technique?

Researchers will implement the less invasive surfactant administration technique and see if it works to treat respiratory distress in preterm infants compared to preterm who did not receive surfactant.

Participants with respiratory distress who are being treated with continuous positive airway pressure and caffeine citrate will:

Receive surfactant replacement therapy by the less invasive surfactant administration technique.

Be monitored for complications Be followed throughout their hospitalization to determine their survival rate.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Implementing LISA Surfactant in Nigeria

NCT05714865

Respiratory Distress Syndrome Neonatal Death

COMPLETED PHASE4

A Multicenter, Randomized, Open Label Trial of a New Animal Extracted Surfactant to Treat RDS in Preterm Infants

NCT02305160

Respiratory Distress Syndrome

COMPLETED PHASE2/PHASE3

Aerosolized Surfactant in Neonatal RDS

NCT02294630

Respiratory Distress Syndrome, Newborn

COMPLETED PHASE1/PHASE2

LISA vs INSURE in the Treatment of Respiratory Distress Syndrome in Preterm Infants

NCT04126382

Preterm Infants

UNKNOWN PHASE2

Less Invasive Surfactant Administration in Late Preterm or Early Term Born Infants

NCT06421506

Respiratory Distress Syndrome Preterm Pregnancy Surfactant Deficiency Syndrome Neonatal

NOT_YET_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The low- and middle-income countries of Sub-Saharan Africa (SSA) carry the highest burden of preterm births and deaths. A primary driver of preterm mortality in SSA is respiratory distress syndrome. Surfactant replacement therapy by the less invasive surfactant administration (LISA) is a technique where the surfactant is administered to a preterm neonate with respiratory distress syndrome managed on continuous positive airway pressure (CPAP), reducing the need for using an invasive mechanical ventilator. In high-income countries, LISA has been shown to be effective in reducing the need for invasive mechanical ventilators and mortality. However, the impact of LISA is unknown in low-resourced settings without ventilators.

The central hypothesis is that implementing LISA in newborn units that care for preterm neonates using standardized CPAP and caffeine citrate will improve survival in preterm neonates.

PICO Outline:

Population: Preterm neonates 750 and 2000 grams or gestational age between 24- and 35 weeks at birth with respiratory distress defined by a Silverman Anderson Score of ≥5, who are spontaneously breathing and on CPAP.

Intervention: Surfactant administered through the less invasive surfactant administration (LISA), technique.

Comparator: Standard of care - standardized CPAP and Caffeine.

Outcome measures: Primary Outcome: All-cause in-hospital survival.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Respiratory Distress Syndrome in Premature Infant RDS of Prematurity Surfactant Deficiency Syndrome Neonatal Premature Birth

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

A stepped wedge cluster randomized controlled trial

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Non-LISA Group

Preterm infants with respiratory distress syndrome who are on continuous positive airway pressure support and being treated with caffeine citrate.

Group Type NO_INTERVENTION

No interventions assigned to this group

LISA Group

Preterm infants with respiratory distress syndrome, who are on continuous positive airway pressure support are treated with caffeine citrate and surfactant through the less invasive surfactant administration technique.

Group Type EXPERIMENTAL

Surfactant

Intervention Type DRUG

Surfactant is instilled into the lungs through a thin catheter passed into the trachea during laryngoscopy while on continuous positive airway pressure (CPAP)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Surfactant

Surfactant is instilled into the lungs through a thin catheter passed into the trachea during laryngoscopy while on continuous positive airway pressure (CPAP)

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Less Invasive Surfactant Administration Technique

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Birth weight between 750 and 2000 grams or gestational age between 24- and 35 weeks.
* Silverman Anderson Score ≥5 before or after CPAP treatment.
* Admitted to a study site within 24 hours of life.

Exclusion Criteria

* Major congenital or genetic anomalies.
* Active pulmonary hemorrhage.
* Major craniofacial anomalies that preclude the successful use of CPAP

Minimum Eligible Age

1 Hour

Maximum Eligible Age

24 Hours

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Osayame Ekhaguere

Assistant Professor of Pediatrics

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Osayame A Ekhaguere, MBBS, MPH

Role: PRINCIPAL_INVESTIGATOR

Indiana University

Helen Nabwera, BMedSci

Role: PRINCIPAL_INVESTIGATOR

Aga Khan University

Olufunke Bolaji, MBBS

Role: PRINCIPAL_INVESTIGATOR

Afe Babalola University

Edgardo Szyld, MD, MS

Role: PRINCIPAL_INVESTIGATOR

Indiana University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.